Shareholder Returns
Information on Sumitomo Pharma’s shareholder returns.
Dividend
In the Mid-term Business Plan 2027, the Company states, "the Company will suspend dividends as negative core operating profit is forecasted for the year ending March 31, 2024 but will resume dividends for the year ending March 31, 2025 as core operating profit is expected to return to positive. A consistent dividend payment will be the aim thereafter." Nevertheless, 1.0 billion yen of core operating profit is forecasted for the year ending March 31, 2025, which is significantly below the assumption stated in the Mid-term Business Plan 2027. Accordingly, the Company regrets to announce that dividends will be suspended for the year ending March 31, 2025.
The Company would like to extend its deepest apologies to its shareholders. The Company will make every effort to promptly recover its performance, and the Company would appreciate your understanding and continued support.
We have not split or consolidated our shares during the periods shown in the table below.
| FY2022 | FY2023 (tentative) | FY2024 (tentative) | |
|---|---|---|---|
| Consolidated dividend payment ratio | ー | ー | ー |
Our basic policy on profit distribution
The Company believes it important to distribute surpluses in an appropriate manner reflecting any improvement in its performance. Accordingly, a performance-linked dividend hike will be considered in addition to consistent dividend payment.
Dividend per share
Share repurchase
No share repurchase is currently taking place.
Shareholder incentives
No shareholder incentive program is currently taking place.